

CITATION REPORT

List of articles citing

Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure

DOI: 10.1016/s0002-9149(99)00059-4
American Journal of Cardiology, 1999, 83, 1201-5.

Source: <https://exaly.com/paper-pdf/30566195/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
258	The role of third-generation beta-blocking agents in chronic heart failure. 1998 , 21, 13-13		79
257	Clinical Pharmacology of Carvedilol. 1999 , 4, 205-218		23
256	Vasodilator Therapy for Chronic Aortic and Mitral Regurgitation. <i>American Journal of the Medical Sciences</i> , 2000 , 320, 202-208	2.2	
255	The Heart Failure Journal Club: a review of publications on heart failure in the American Journal of Cardiology. <i>European Journal of Heart Failure</i> , 2000 , 2, 461-470	12.3	
254	Role of beta blockers in congestive heart failure. 2000 , 6, 299-312		2
253	Receptors in cardiovascular disease: review and introduction. 2000 , 74, 157-61		3
252	Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure. <i>American Journal of Cardiology</i> , 2000 , 86, 1032-5, A10-1	3	20
251	Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure. <i>Journal of Nuclear Cardiology</i> , 2000 , 7, 3-7	2.1	28
250	The role of cardiac imaging in optimizing therapy in heart failure. <i>Journal of Nuclear Cardiology</i> , 2000 , 7, 81-4	2.1	1
249	The effects of neurohormonal antagonism on pathologic left ventricular remodeling in heart failure. 2000 , 2, 90-8		3
248	Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure. 2000 , 2, 225-32		3
247	Beta-adrenergic blocking agents in heart failure. 2000 , 75, 339-60		1
246	Perioperative Treatment of Congestive Heart Failure. 2000 , 4, 223-235		
245	Receptors in cardiovascular disease: review and introduction. 2000 , 31, 157-161		
244	beta-blocker improvement in diastolic performance: the yin and yang of ventricular function changes. 2000 , 139, 584-6		6
243	beta-adrenergic receptor blockade in chronic heart failure. <i>Circulation</i> , 2000 , 101, 558-69	16.7	823
242	Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 2072-80	15.1	221

241	Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 569-82	15.1	1782
240	Polypharmacy of heart failure. Creating a rational pharmacotherapeutic protocol. 2001 , 19, 583-96, viii		12
239	Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade. 2001 , 33, 487-501		60
238	Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. 2001 , 33, 887-905		220
237	Aldosterone inhibition and heart failure: too good to be true?. 2001 , 141, 1-2		36
236	Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy--Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. 2001 , 141, 645-52		66
235	The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. 2001 , 142, 340-9		48
234	Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol. 2001 , 142, 704-13		42
233	Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. 2001 , 138, 505-11		146
232	Carvedilol--a new dimension in pediatric heart failure therapy. 2001 , 138, 457-8		7
231	CAPRICORN: a story of alpha allocation and beta-blockers in left ventricular dysfunction post-MI. 2001 , 78, 109-13		7
230	Beta-blockade in heart failure: selective versus nonselective agents. 2001 , 1, 3-14		14
229	Medical management of chronic heart failure in children. 2001 , 1, 37-44		18
228	Carvedilol versus other beta-blockers in heart failure. 2001 , 10, 971-80		5
227	The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. 2001 , 2, 20-23		51
226	Carvedilol in the failing heart. 2001 , 24, 757-66		11
225	Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. <i>Journal of Nuclear Cardiology</i> , 2001 , 8, 4-9	2.1	30
224	Effect of revascularization on left ventricular remodeling in patients with heart failure from severe chronic ischemic left ventricular dysfunction. <i>American Journal of Cardiology</i> , 2001 , 88, 624-9	3	59

223	The Cardiovascular Continuum [Pathophysiology and Targets for Therapy. 2001 , 1-15		
222	Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. 2002 , 346, 1357-65		402
221	Carvedilol inhibits platelet-derived growth factor-induced signal transduction in human cardiac fibroblasts. 2002 , 39, 576-89		10
220	Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy. 2002 , 11, 1529-36		21
219	[Treatment of heart failure with beta-receptor-blockers]. 2002 , 127, 682-8		6
218	Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. <i>Circulation</i> , 2002 , 105, 1304-10	16.7	228
217	Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status. 2002 , 41, 1147-52		1
216	Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig. 2002 , 39, 746-53		3
215	Proliferative signaling and disease progression in heart failure. 2002 , 66, 225-31		19
214	Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. <i>European Journal of Heart Failure</i> , 2002 , 4, 765-70	12.3	35
213	Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?. 2002 , 4, 771-8		19
212	Effect of carvedilol therapy on functional mitral regurgitation, ventricular remodeling, and contractility in patients with heart failure due to left ventricular systolic dysfunction. 2002 , 34, 177-8		27
211	Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated?. 2002 , 144, 373-6		35
210	Coordinate Changes in Myosin Heavy Chain Isoform Gene Expression Are Selectively Associated With Alterations in Dilated Cardiomyopathy Phenotype. 2002 , 8, 750-760		82
209	Carvedilol reverses elevated pulmonary vascular resistance in a child with dilated cardiomyopathy. 2002 , 23, 100-2		5
208	Maladaptive growth in the failing heart: the cardiomyopathy of overload. 2002 , 16, 245-9		62
207	Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy. 2003 , 17, 349-60		35
206	Prevalence and severity of mitral regurgitation in chronic systolic heart failure. <i>American Journal of Cardiology</i> , 2003 , 91, 360-2	3	135

205	Prevalence, predictors, and prognostic implications of improvement in left ventricular systolic function and clinical status in patients >70 years of age with recently diagnosed systolic heart failure. <i>American Journal of Cardiology</i> , 2003 , 92, 166-72	3	27
204	Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. 2003 , 7, 1-10		37
203	Favorable cardiac remodeling in dilated cardiomyopathy: potential assessment with serial myocardial perfusion imaging. <i>Journal of Nuclear Cardiology</i> , 2003 , 10, 336-7	2.1	
202	Catheter-based approach to mitral regurgitation. 2003 , 16, 523-34		38
201	Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances. 2003 , 8, 75-89		33
200	Pathophysiology of heart failure: identifying targets for pharmacotherapy. 2003 , 87, 303-16		20
199	Beta-blockers and reverse remodeling: what are the implications?. 2003 , 145, 200-2		15
198	Improved systemic ventricular function after carvedilol administration in a patient with congenitally corrected transposition of the great arteries. 2003 , 22, 198-201		25
197	Heart failure: the frequent, forgotten, and often fatal complication of diabetes. 2003 , 26, 2433-41		325
196	??-blockers in heart failure. 2003 , 13, 375-377		
195	Beta-blockade in chronic heart failure: does it work in everyone?. 2003 , 18, 400-5		2
194	Plastic bronchitis after Fontan operation: treatment with stent fenestration of the Fontan circuit. 2004 , 90, 801		33
193	The impact of baseline left ventricular size and mitral regurgitation on reverse left ventricular remodelling in response to carvedilol: size doesn't matter. 2004 , 90, 800-1		9
192	Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy. 2004 , 62, 450-9		19
191	Ventricular remodeling in heart failure and the effect of beta-blockade. <i>American Journal of Cardiology</i> , 2004 , 93, 43B-8B	3	39
190	Advantages of a third-generation beta-blocker in patients with diabetes mellitus. <i>American Journal of Cardiology</i> , 2004 , 93, 49B-52B	3	30
189	Mitral regurgitation in chronic heart failure: more questions than answers?. 2004 , 6, 96-9		3
188	Evolving concepts in left ventricular systolic and diastolic remodeling: implications for therapy. 2004 , 6, 200-4		1

187	Efectos del carvedilol en la capacidad funcional, función ventricular izquierda, catecolaminas y estrés oxidativo en pacientes con insuficiencia cardíaca crónica. 2004 , 57, 1053-1058		5
186	Effects of Carvedilol on Functional Capacity, Left Ventricular Function, Catecholamines, and Oxidative Stress in Patients With Chronic Heart Failure. 2004 , 57, 1053-1058		
185	Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. 2004 , 107, 539-57		250
184	Effects of carvedilol therapy on restrictive diastolic filling pattern in chronic heart failure. 2004 , 147, E2		16
183	Aldosterone antagonism and congestive heart failure: a new look at an old therapy. 2004 , 19, 301-8		11
182	Prognostic implications of echocardiography in advanced heart failure. 2004 , 19, 238-49		39
181	Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure. 2005 , 45, 563-8		24
180	Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. 2005 , 15, 227-34		141
179	An echocardiographic analysis of the long-term effects of carvedilol on left ventricular remodeling, systolic performance, and ventricular filling patterns in dilated cardiomyopathy. 2005 , 22, 547-54		8
178	Ventricular remodeling in children with left ventricular dysfunction secondary to various cardiomyopathies. <i>American Journal of Cardiology</i> , 2005 , 96, 1157-61	3	14
177	Drugs for left ventricular remodeling in heart failure. <i>American Journal of Cardiology</i> , 2005 , 96, 10L-18L	3	105
176	Molecular remodeling in the failing human heart. 2005 , 2, 5-9		5
175	Heart failure following anterior myocardial infarction: an indication for ventricular restoration, a surgical method to reverse post-infarction remodeling. 2004 , 9, 241-54		7
174	Pharmacological left ventricular reverse remodeling in elderly patients receiving optimal therapy for chronic heart failure. <i>European Journal of Heart Failure</i> , 2005 , 7, 1040-8	12.3	15
173	Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. <i>European Journal of Heart Failure</i> , 2005 , 7, 1112-7	12.3	61
172	Preservation of cardiac extracellular matrix by passive myocardial restraint: an emerging new therapeutic paradigm in the prevention of adverse remodeling and progressive heart failure. <i>Circulation</i> , 2005 , 112, 1245-7	16.7	5
171	Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts. <i>Circulation</i> , 2005 , 112, 745-58	16.7	358
170	Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. 2005 , 18, 1563-9		51

169	Is mitral regurgitation a viable treatment target in heart failure? The plot just thickened. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 388-90	15.1	26
168	Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. 2005 , 68, 25-48		50
167	Direct effects of 3 combinations of enalapril, metoprolol, and spironolactone on cardiac remodeling in dilated cardiomyopathic hamsters. 2006 , 12, 752-8		5
166	Reducing the risk of sudden death in heart failure with beta-blockers. 2006 , 12, 734-46		32
165	The use of carvedilol in pediatric heart failure. 2006 , 6, 35-42		4
164	Functional mitral regurgitation in heart failure. 2006 , 7, 514-23		7
163	Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. 2001 , 19, 152-71		92
162	Left ventricular shape index assessed by gated stress myocardial perfusion SPECT: initial description of a new variable. <i>Journal of Nuclear Cardiology</i> , 2006 , 13, 652-9	2.1	23
161	[Aortic stenosis]. <i>Clinical Research in Cardiology</i> , 2006 , 95, 620-41	6.1	28
160	[Mitral regurgitation]. 2006 , 47, 275-283; quiz 284-5		1
159	The frequency, impact, and management of mitral regurgitation in patients with heart failure. 2006 , 8, 226-31		4
158	Mitral regurgitation progression following isolated coronary artery bypass surgery: frequency, risk factors, and potential prevention strategies. 2006 , 29, 348-53		27
157	Mild--moderate ischemic mitral regurgitation: should it be treated together with CABG?. 2006 , 29, 353-4		2
156	Ischemic mitral regurgitation: mechanisms and echocardiographic classification. 2008 , 9, 207-21		67
155	Beta-blocker therapy of heart failure: an update. 2007 , 8, 289-98		2
154	Afterload reduction may halt and beta-adrenergic blockade may worsen progression of left ventricular dysfunction in patients with chronic compensated mitral regurgitation: a retrospective cohort study. 2007 , 58, 196-202		5
153	Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. 2007 , 17, 277-82		72
152	Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy. 2007 , 13, 304-11		42

151	Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers. 2007 , 26, 1170-6		16
150	Predictors of therapeutic response to beta-blockers in patients with heart failure in Taiwan. 2007 , 106, 641-8		9
149	Carvedilol in Dogs with Dilated Cardiomyopathy. 2007 , 21, 1272-1279		10
148	RATIONAL CHOICE OF β ADRENOBLOCKERS IN CHRONIC HEART FAILURE THERAPY. 2007 , 3, 60-68		
147	Structural and electrical remodeling as therapeutic targets in heart failure. 2007 , 40, S1-7		12
146	A radial global dyssynchrony index as predictor of left ventricular reverse remodeling after cardiac resynchronization therapy. 2008 , 31, 819-27		7
145	Reverse of left ventricular volumetric and structural remodeling in heart failure patients treated with cardiac resynchronization therapy. <i>American Journal of Cardiology</i> , 2008 , 101, 651-7	3	26
144	Oxidative stress and left ventricular remodelling after myocardial infarction. 2009 , 81, 457-64		324
143	Surgery for severe mitral regurgitation and left ventricular failure: what do we really know?. 2008 , 14, 145-50		15
142	Dilated Cardiomyopathy and Cardiac Transplantation. 2008 , 247-257		1
141	Pilot study to assess the influence of beta-blockade on mitral regurgitant volume and left ventricular work in degenerative mitral valve disease. <i>Circulation</i> , 2008 , 118, 1041-6	16.7	24
140	Advances in the surgical treatment of heart failure. 2008 , 23, 249-53		18
139	Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction. 1-30		
138	Ischemic mitral regurgitation: a complex multifaceted disease. 2009 , 112, 244-59		105
137	Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. <i>European Heart Journal</i> , 2009 , 30, 1863-72	9.5	46
136	beta-Adrenergic receptor blockers and heart failure risk after myocardial infarction: a critical review. 2009 , 6, 220-8		3
135	Strategies to attenuate pathological remodeling in heart failure. 2009 , 24, 223-9		12
134	Echocardiographic evaluation of children with systemic ventricular dysfunction treated with carvedilol. 2010 , 31, 780-4		16

133	Influence of cardiac shape on left ventricular twist. 2010 , 108, 146-51		63
132	Fetal growth restriction results in remodeled and less efficient hearts in children. <i>Circulation</i> , 2010 , 121, 2427-36	16.7	289
131	Mitral valve surgery in advanced heart failure. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 271-82	15.1	92
130	Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 392-406	15.1	272
129	Section 7: Heart Failure in Patients With Reduced Ejection Fraction. 2010 , 16, e73-e97		
128	A randomised, placebo-controlled trial of carvedilol in early familial dilated cardiomyopathy. 2011 , 20, 566-73		10
127	Antagonism of the Sympathetic Nervous System in Heart Failure. 2011 , 674-693		3
126	Current pharmacologic management of pediatric heart failure in congenital heart disease. 2011 , 9, 619-28		9
125	Effect of carvedilol on heart failure in patients with a functionally univentricular heart. 2011 , 75, 1394-9		36
124	Valvular Heart Disease in the Elderly. 2011 , 5, 413-421		1
123	Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. 2012 , 18, 338-49		20
122	Assessment of ventricular remodeling in heart failure clinical trials. 2012 , 9, 328-36		16
121	Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. 2012 , 17, 325-44		240
120	Ischemic mitral regurgitation: not only a bystander. 2012 , 14, 180-9		11
119	Left ventricular mechanics following restrictive mitral annuloplasty for functional mitral regurgitation: two-dimensional speckle tracking echocardiographic study. 2012 , 29, 445-50		4
118	Translational Approach to Heart Failure. 2013 ,		2
117	Effect of race on left ventricular ejection fraction decline after initial improvement with beta blockers in patients with non-ischemic cardiomyopathy: a retrospective analysis. 2013 , 13, 183-90		1
116	Plasma active matrix metalloproteinase 9 and indices of diastolic function in patients with preserved systolic function. 2013 , 167, 1242-6		6

115	Valvular heart disease in older adults: evolving technology to meet the needs of aging patients. 2013 , 9, 205-215		3
114	Abnormal early diastolic intraventricular flow kinetic energy index assessed by vector flow mapping in patients with elevated filling pressure. <i>European Heart Journal Cardiovascular Imaging</i> , 2013 , 14, 253-60	4.1	31
113	Assisted reproductive technologies are associated with cardiovascular remodeling in utero that persists postnatally. <i>Circulation</i> , 2013 , 128, 1442-50	16.7	103
112	Percutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling. 2013 , 6, 522-30		40
111	Secondary mitral regurgitation in heart failure with reduced or preserved left ventricular ejection fraction. 2013 , 125, 110-7		32
110	Effects of early, late, and long-term nonselective β blockade on left ventricular remodeling, function, and survival in chronic organic mitral regurgitation. 2013 , 6, 756-62		8
109	Effects of β adrenergic blockade on left ventricular remodeling among Hispanics and African Americans with chronic heart failure. 2013 , 36, 595-602		6
108	Late cardiac remodeling after primary percutaneous coronary intervention-five-year cardiac magnetic resonance imaging follow-up. 2013 , 77, 81-8		31
107	3D Echo pilot study of geometric left ventricular changes after acute myocardial infarction. 2013 , 101, 43-51		11
106	Modeling the effects of β_1 -adrenergic receptor blockers and polymorphisms on cardiac myocyte Ca^{2+} handling. 2014 , 86, 222-30		14
105	A fetal cardiovascular score to predict infant hypertension and arterial remodeling in intrauterine growth restriction. <i>American Journal of Obstetrics and Gynecology</i> , 2014 , 210, 552.e1-552.e22	6.4	55
104	A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling. 2014 , 19, 799-814		22
103	Postsystolic shortening by myocardial deformation imaging as a sign of cardiac adaptation to pressure overload in fetal growth restriction. 2014 , 7, 781-7		53
102	Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial. <i>European Journal of Heart Failure</i> , 2014 , 16, 907-14	14.3	21
101	Cardiac and Vascular Receptors and Signal Transduction. 2015 , 251-277		1
100	Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1231-1248	15.1	252
99	Mitral Regurgitation in Heart Failure: Mechanisms and Therapeutic Options. 2015 , 1187-1199		
98	Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. 2016 , 34, 261-7		5

97	Pharmacologic and Endovascular Reversal of Left Ventricular Remodeling. 2016 , 22, 829-39		11
96	Functional Mitral Regurgitation: Appraising the Evidence Behind Recommended Treatment Strategies. 2016 , 18, 128		
95	Pharmacogenomics of heart failure: a systematic review. 2016 , 17, 1817-1858		8
94	Functional mitral regurgitation in patients with heart failure and depressed ejection fraction. 2016 , 31, 483-92		5
93	Myocardial reverse remodeling: how far can we rewind?. 2016 , 310, H1402-22		23
92	Radionuclide Imaging Applications in Cardiomyopathies and Heart Failure. 2016 , 18, 23		4
91	Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. <i>Heart and Vessels</i> , 2016 , 31, 1239-46	2.1	11
90	Abnormal Fetal Findings Associated With a Global Sphericity Index of the 4-Chamber View Below the 5th Centile. 2017 , 36, 2309-2318		19
89	Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model. 2017 , 5, 2050312117700057		3
88	Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next?. 2017 , 60, 226-236		16
87	Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation. 2017 , 424, 87-98		18
86	Differential effect of assisted reproductive technology and small-for-gestational age on fetal cardiac remodeling. 2017 , 50, 63-70		11
85	Automatic myocardial segmentation by using a deep learning network in cardiac MRI. 2017 ,		12
84	Myocardial recovery and the failing heart: medical, device and mechanical methods. 2014 , 80, 55-60		6
83	Contemporary Management of Ischemic Mitral Regurgitation: A Review. 2018 , 131, 887-895		9
82	The effects of heart rate control in chronic heart failure with reduced ejection fraction. 2018 , 23, 527-535		8
81	24-segment sphericity index: a new technique to evaluate fetal cardiac diastolic shape. 2018 , 51, 650-658		34
80	Fetal cardiac remodeling in twin pregnancy conceived by assisted reproductive technology. 2018 , 51, 94-100		8

79	Right and left ventricular 24-segment sphericity index is abnormal in small-for-gestational-age fetuses. 2018 , 52, 243-249		12
78	Cardiovascular adaptation to extrauterine life after intrauterine growth restriction. 2018 , 28, 284-291		7
77	Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart. 2018 , 23, 37-54		27
76	Clinical and histopathological effects of heart failure drug therapy in advanced heart failure patients on chronic mechanical circulatory support. <i>European Journal of Heart Failure</i> , 2018 , 20, 164-174 ^{12.3}		19
75	Functional Mitral Regurgitation: An Interventional Cardiologist's Perspective. 2018 , 26, 230-238		1
74	Clinical manifestations, diagnosis, and treatment of ischemic mitral regurgitation: a review. <i>Journal of Thoracic Disease</i> , 2018 , 10, 6969-6986	2.6	5
73	Left and Right Ventricular Remodeling. 2018 , 171-185		1
72	OBSOLETE: Left and Right Ventricular Remodeling. 2018 ,		
71	OBSOLETE: Neurohormonal Blockade. 2018 ,		
70	Echocardiography in Heart Failure. 2018 , 126-141		
69	Impact of pre-eclampsia on the cardiovascular health of the offspring: a cohort study protocol. 2018 , 8, e024331		7
68	Endocardial linear infarct exclusion technique for non- <i>ischaemic</i> functional mitral regurgitation caused by cardiac sarcoidosis: a case report. 2018 , 2, yty046		
67	Neurohormonal Blockade. 2018 , 459-476		
66	Evolution of mitral regurgitation in patients with heart failure referred to a tertiary heart failure clinic. <i>ESC Heart Failure</i> , 2019 , 6, 936-943	3.7	3
65	The Choice of Treatment in Ischemic Mitral Regurgitation With Reduced Left Ventricular Function. 2019 , 108, 1901-1912		9
64	Contrasting Effects of Pharmacological, Procedural, and Surgical Interventions on Proportionate and Disproportionate Functional Mitral Regurgitation in Chronic Heart Failure. <i>Circulation</i> , 2019 , 140, 779-789	16.7	36
63	Treatment of functional mitral regurgitation in chronic heart failure: can we get a proof of concept from the MITRA-FR and COAPT trials?. <i>European Journal of Heart Failure</i> , 2019 , 21, 852-861	12.3	53
62	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. 2019 , 21, 1277-1290		43

61	The Role of Arterial Hypertension in Mitral Valve Regurgitation. 2019 , 21, 20		0
60	Assessing cardiovascular remodelling in fetuses and infants conceived by assisted reproductive technologies: a prospective observational cohort study protocol. 2019 , 9, e031452		2
59	Secondary mitral regurgitation: percutaneous edge-to-edge repair on the cutting edge?. 2019 , 34, 185-193		
58	Automatic quantification of the LV function and mass: A deep learning approach for cardiovascular MRI. <i>Computer Methods and Programs in Biomedicine</i> , 2019 , 169, 37-50	6.9	19
57	Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. <i>Circulation</i> , 2019 , 139, 1354-1365	16.7	140
56	Assessing LV remodeling in nuclear cardiology. <i>Journal of Nuclear Cardiology</i> , 2019 , 26, 233-235	2.1	1
55	Fetal cardiac remodeling and dysfunction is associated with both preeclampsia and fetal growth restriction. <i>American Journal of Obstetrics and Gynecology</i> , 2020 , 222, 79.e1-79.e9	6.4	26
54	Left Ventricular Size and Secondary MR: A Harbinger of PMVR Success?. <i>Cardiovascular Revascularization Medicine</i> , 2020 , 21, 865-866	1.6	
53	Left ventricle segmentation using a Bayesian approach with distance dependent shape priors. <i>Biomedical Physics and Engineering Express</i> , 2020 , 6, 045013	1.5	1
52	Treatment options for ischemic mitral regurgitation: A meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 ,	1.5	14
51	Mitral regurgitation: lessons learned from COAPT and MITRA-Fr. <i>Journal of Thoracic Disease</i> , 2020 , 12, 2936-2944	2.6	4
50	Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2020 , 41, 2799-2810	9.5	17
49	Percutaneous Mitral Valve Intervention Using MitraClip for Functional Mitral Regurgitation and Heart Failure. <i>International Heart Journal</i> , 2021 , 62, 4-8	1.8	0
48	The advantages, pitfalls and limitations of guideline-directed medical therapy in patients with valvular heart disease. <i>European Journal of Heart Failure</i> , 2021 , 23, 1325-1333	12.3	3
47	The role of transcatheter mitral valve leaflet approximation for the treatment of secondary mitral regurgitation: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2021 , 18, 261-272	3.5	0
46	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021 ,	9.5	29
45	Alterations in Intracardiac Flow Patterns Affect Mitral Leaflets Dynamics in a Model of Ischemic Mitral Regurgitation. <i>Cardiovascular Engineering and Technology</i> , 2021 , 1	2.2	0
44	Effect of oral tolvaptan for 1 year in patients with functional mitral regurgitation. <i>Heart and Vessels</i> , 2021 , 1	2.1	

43	Cardiac and Vascular Receptors and Signal Transduction. 2009 , 191-218		1
42	Mitral Valve Diseases. 2007 , 397-430		2
41	Radionuclide Imaging in Heart Failure. 2010 , 468-482		1
40	Southwestern Internal Medicine Conference. <i>American Journal of the Medical Sciences</i> , 2000 , 320, 202-208		13
39	Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat. <i>PLoS ONE</i> , 2013 , 8, e75557	3-7	56
38	Ischemic Mitral Regurgitation: From New Understanding to New Solutions Role of Echocardiography. <i>Journal of Echocardiography</i> , 2006 , 4, 1-18	1.6	6
37	Epidemiology, Pathophysiology, and Management of Native Atrioventricular Valve Regurgitation in Heart Failure Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 713658	5-4	
36	Outpatient Therapy. <i>Developments in Cardiovascular Medicine</i> , 2000 , 149-200		
35	The Role of Multiple Adrenergic Blockade in Coronary Artery Disease and Myocardial Infarction. 2001 , 39-53		
34	Cardiac Remodeling and Its Prevention. 2005 , 83-100		
33	Timing of Intervention for Chronic Valve Regurgitation: The Role of Echocardiography. 2007 , 430-458		
32	Adrenoceptor-Linked Signal Transduction Mechanisms in Congestive Heart Failure. 2008 , 27-49		
31	Pacemaker Therapy for Advanced Ischemic Heart Disease. 2009 , 49-67		
30	Ischemic Mitral Regurgitation. 2009 , 260-273		1
29	The Mitral Valve Disease. 2009 , 1-72		
28	Pathophysiology of Heart Failure. 2010 , 1-27		
27	Echocardiographic assessment of the relationship between left ventricular geometry and dyssynchrony. <i>Choonpa Igaku</i> , 2010 , 37, 499-505	0	
26	Chronic Ischemic Mitral Regurgitation. 2010 , 43-51		1

25	Spherical ventricular chamber is a predictor of poor prognosis of heart failure with preserved ejection fraction. <i>Choonpa Igaku</i> , 2011 , 38, 103-110		0
24	Krankheiten des Herzens. 2012 , 335-393		
23	Heart Failure. 117-142		
22	Tailored Approach to Functional Mitral Regurgitation. 2013 , 317-333		
21	Mitral Regurgitation. 329-363		
20	OBSOLETE: Echocardiography in Heart Failure. 2018 ,		
19	Secondary Mitral Regurgitation. <i>Cardiovascular Medicine</i> , 2020 , 125-130		0.1
18	Krankheiten des Herzens. 2008 , 311-373		
17	Cardiac and Vascular Receptors and Signal Transduction. 2005 , 149-159		1
16	Beta-adrenergic receptor antagonists and chronic heart failure in children. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 847-54	2.9	3
15	Efficacy of Carvedilol in Patients with Dilated Cardiomyopathy due to Beta-thalassemia major; a Double-blind Randomized Controlled Trial. <i>Iranian Journal of Pediatrics</i> , 2010 , 20, 277-83	1	5
14	Percutaneous Edge-to-Edge Mitral Valve Repair for Functional Mitral Regurgitation. <i>International Journal of Heart Failure</i> , 4,	1.3	1
13	Guideline directed medical therapy and reduction of secondary mitral regurgitation.. <i>European Heart Journal Cardiovascular Imaging</i> , 2022 ,	4.1	0
12	Optimization of guideline-directed medical treatment to reduce secondary mitral regurgitation: treat the ventricle, not only the valve.. <i>European Heart Journal Cardiovascular Imaging</i> , 2022 ,	4.1	
11	Functional mitral regurgitation - a moving target in patients with heart failure.. <i>Trends in Cardiovascular Medicine</i> , 2022 ,	6.9	
10	New Perspective on Pathophysiology and Management of Functional Mitral Regurgitation.. <i>Trends in Cardiovascular Medicine</i> , 2022 ,	6.9	0
9	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure.. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	0
8	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Circulation</i> , 2022 , 101161CIR0000000000001063	16.7	35

7	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Journal of the American College of Cardiology</i> , 2022 ,	15.1	49
6	Erworbene und angeborene Herzvitien Begutachtung. <i>Springer Reference Medizin</i> , 2022 , 1-14		o
5	Guideline-directed medical therapy after transcatheter edge-to-edge mitral valve repair. <i>Heart</i> , heartjnl-2022-320826	3.0	o
4	Role of Phospholipase C in Catecholamine-induced Increase in Myocardial Protein Synthesis; <i>Canadian Journal of Physiology and Pharmacology</i> ,	2.4	o
3	Effect of ß-blocker on patients with moderate functional mitral regurgitation undergoing surgical aortic valve replacement. <i>ESC Heart Failure</i> ,	3.7	
2	Medical Therapy for Functional Mitral Regurgitation. 2022 , 15,		o
1	Left ventricle segmentation combining deep learning and deformable models with anatomical constraints. 2023 , 104366		o